Mitralign Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mitralign Inc.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Coronavirus Update: Double-Mutant Strain Discovered, India Puts Temporary Hold On AZ Vaccine Exports
Concern in India as a double-mutant strain with E484Q and L452R escape mutations has been found in the state of Maharashtra.
Tricuspid Version of Abbott’s MitraClip Improves Short-Term Outcomes In TRILUMINATE
Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.
Abbott Launches Feasibility Trial Of Tricuspid Version Of MitraClip
The TRILUMINATE trial will evaluate safety and effectiveness of its Tricuspid Valve Repair System for treating symptomatic moderate-to-severe tricuspid regurgitation. The device is similar to Abbott's successful MitraClip catheter-based device for treating mitral regurgitation.
Company Information
- Industry
-
Medical Devices
- Surgical Equipment & Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice